Video

Dr. Rampal on Pelabresib With or Without Ruxolitinib in Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the investigation of pelabresib (CPI-0610) with or without ruxolitinib (Retuxan) in patients with myelofibrosis.

The phase 1/2 MANIFEST trial (NCT02158858) examined the use of pelabresib with and without ruxolitinib in patients with myelofibrosis. The MANIFEST study featured 3 arms: the combination of pelabresib and ruxolitinib in previously untreated patients, single-agent pelabresib in patients who were already receiving ruxolitinib, and single-agent pelabresib arm for patients previously treated with a JAK inhibitor, Rampal explains.

Data showed that in the up-front treatment setting, patients treated with the combination experienced a benefit in spleen volume response—defined as a 35% or greater reduction in spleen volume—compared favorably with historical data for single-agent ruxolitinib, Rampal adds.

The phase 3 MANIFEST-2 trial (NCT04603495) will further investigate the combination of pelabresib and ruxolitinib vs placebo plus ruxolitinib in patients with myelofibrosis who have not received prior treatment with a JAK inhibitor, Rampal concludes.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Binod Dhakal, MD
Sheldon M. Feldman, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.